Table 30Evidence profile of the comparative tolerability and harms of constipation drugs in children

Evidence Profile: Comparative safety of constipation drugs in children
No. of Studies/ PatientsDesignQualityConsistencyDirectnessMagnitude of EffectOther modifying factors*Overall Grade of the Evidence
PEG 3350 vs. Lactulose
1 RCT / 137 patientsRCTPoor, Serious methodological problemsN/AYes for chronic constipation

No for IBS
NRNoneLow

*Imprecise or sparse data; a strong or very strong association; high risk of reporting bias; dose response gradient; effect of plausible residual confounding; IBS: Irritable Bowel Syndrome; NR: not reported; PEG: polyethylene glycol; RCT: randomized controlled trial

From: Results

Cover of Drug Class Review: Constipation Drugs
Drug Class Review: Constipation Drugs: Final Report [Internet].
Gartlehner G, Jonas DE, Morgan LC, et al.
Portland (OR): Oregon Health & Science University; 2007 Sep.
Copyright © 2007, Oregon Health & Science University, Portland, Oregon.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.